Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIASTIN: Avastin or Lucentis vs Triamcinolone in Diabetic Macular Edema
NCT00682539Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2007
- Primary completion
- Jul 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bevacizumab and ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by Medical University of Vienna. Primary endpoints: Change in Visual Acuity at 12 months and Change in Macular Edema at 12 months. Started Oct 2007; status: completed.
02
Drugs
bevacizumabranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT00682539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00682539.